stockrow
Saturday 7 November 2026
Export ARMP’s income statement to Excel — free account
Armata Pharmaceuticals, Inc.
ARMP Healthcare Biotechnology
Armata Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 5.22% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +548.9%
- Free cash flow
- −18.0%
- Total debt
- +152.4%
Quarter to June 2026, against a year earlier
3.37
0.37
+12.33%
Follow ARMP
Alert me
Armata Pharmaceuticals, Inc. (ARMP) P/E ratio
Armata Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 3.7× (March 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 32 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.7×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTX Nkarta, Inc. compare | n/m |
| CHRS Coherus Oncology, Inc. compare | n/m |
| FHTX Foghorn Therapeutics Inc. compare | n/m |
| PYPD PolyPid Ltd. compare | n/m |
| CDXS Codexis, Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HUMA Humacyte, Inc. compare | n/m |
| ARMP Armata Pharmaceuticals, Inc. | n/m |
| ENGN enGene Therapeutics Inc compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)